There is only one question that a manufacturer has to answer before she shouts Eureka. Can she prove it? Especially when it is a food product that claims to offer relief to two of the most widely prevalent lifestyle diseaseshigh blood pressure and high blood sugar.

Dressed in blue and white, colour coordinated with cans of Fortune Vivo oil, Bollywood actor Parineeti Chopra (whose healthy diet and lean body have also made news) promoted Vivo as an oil that offered relief to diabetes patients and wellness to the health conscious. Standing next to her, Adani Wilmar’s chief executive Atul Chaturvedi and chief operating officer Angshu Mallick looked pleased with themselves for having launched Fortune brand’s first blended oil.

A joint venture between Adani Enterprises and Singapore’s Wilmar Group, Adani Wilmar already had the status of a market leader in edible oils with about 19% of the market share in 2016. With eight pure oils sold under the Fortune brand, Fortune Vivo, the ninth one, is a blend of 20% cold-pressed unrefined sesame oil and 80% physically refined rice bran oil. It was supposed to be the company’s trump card. Because the oil combination, it claimed, was unique and could miraculously reduce high blood sugar level, improve insulin sensitivity and lower high blood pressure. It expected the new brand to add 2-3% to its existing Rs 8,883 crore revenue and later in the year said it’d invest Rs 600 crore in a new oil processing plant in Odisha.

Expectation

AdanI Wilmar expected the new brand to add 2-3% to its existing Rs 8,883 crore revenue

That was in February 2016. A year later, in January, the Ahmedabad City Civil Court pricked the claim bubble of the edible oil magnate when it said, “Fortune Vivo diabetes care oil with health claim is misleading with ambiguity, and it will affect the health of the general public.” The court ruling came in favour of the Advertising Standard Council of India (ASCI), which Adani Wilmar had dragged to court when the former called its bluff on the claims.

For those who follow the industry, the past year has seen India’s largest edible oil company slug it out with regulators and consumer watchdogs. The Food Safety and Standards Authority of India (FSSAI) has slapped Fortune Vivo with numerous notices and is now investigating multiple complaints.

The boldness of its claim, the flimsiness of its evidence and the grandeur of its marketing may have singled out Adani Wilmar but it is not the only brand staking health claims. Oil companies are increasingly adding labels with claims they cannot deliver.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at support@the-ken.com with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at info@the-ken.com or follow us on Twitter.